Development of nucleic acid-based vaccines against gonorrhea

开发基于核酸的淋病疫苗

基本信息

  • 批准号:
    10539860
  • 负责人:
  • 金额:
    $ 25.13万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-05-19 至 2024-04-30
  • 项目状态:
    已结题

项目摘要

ABSTRACT Gonorrhea affects over 87 million people annually globally. In 2019, over 600,000 cases of gonorrhea were reported to the CDC, a 92% increase since the historic low in the US in 2009. However, the true incidence of cases annually in the US is estimated to be ~1.5 million. The spread of antimicrobial resistance has severely limited treatment options – currently, ceftriaxone is the only approved first line of treatment. A safe and effective vaccine against gonorrhea is urgently needed. Lipooligosaccharide (LOS) is the most abundant molecule on the gonococcal surface and plays multifaceted roles in bacterial virulence. A LOS epitope recognized by mAb 2C7 (therefore called the 2C7 epitope) is expressed by >95% of Ng in vivo; Ng mutants that do not express the 2C7 epitope are attenuated in mice. Our group has developed a peptide mimic (mimitope) of the 2C7 epitope, which when configured as a multi-antigen peptide (MAP) elicits bactericidal Abs and attenuates Ng colonization in mice. Further, we have elucidated the mechanism of action of MAP as complement-mediated killing (killing through membrane attack complex), strongly suggesting serum bactericidal activity as a mechanistic correlate of protection. In a collaborative venture with Evaxion Biotech, we screened 30 antigens that were identified by EDEN, Evaxion’s proprietary in silico platform, for immunogenicity, bactericidal activity and efficacy in the mouse vaginal colonization model. These studies identified two cell division proteins as promising candidates based on efficacy in vivo. When configured as a fusion protein (chimera), the cell division proteins showed improved ac- tivity in vivo compared to individual proteins and currently is our lead protein vaccine candidate. DNA and mRNA vaccines have proven very successful in the fight against the Covid-19 pandemic. These platforms elicit high levels of protection, have proven safe, are rapidly adaptable and economical. Here, we will leverage these two newer vaccine platforms to deliver the protective gonococcal antigens. A multivalent vaccine has the advantage of broader strain coverage, improved efficacy and would also raise the barrier for development of resistance. In Aim 1, we will evaluate DNA vaccine constructs that contain the 2C7 LOS mimitope (PEP1) configured as an octameric concatemer (PEP1_OCT), the cell division protein chimera, or a combination of the two. Serum will be assessed for antibody titers and complement-dependent bactericidal activity, as well durability of responses. Comparisons will be made with the protein versions of these vaccines currently under development. Mucosal (vaginal) Ab responses will also be measured. T cell responses will be measured by ELISpot. Based on data in vitro, the lead DNA vaccine formulation(s) will be assessed for efficacy in the mouse vaginal colonization model. In Aim 2 the constructs described in Aim 1 will be expressed using an mRNA vaccine delivery platform. As in Aim 1, we will evaluate Ab titers in serum and vaginal fluid, measure serum bactericidal activity, T cell responses and efficacy of the lead mRNA vaccine formulation(s) in the mouse model of gonorrhea. Successful completion of the work in this proposal will identify a lead gonococcal DNA and/or mRNA vaccine for further pre-clinical development.
摘要 淋病每年影响全球超过8700万人。2019年,超过60万例淋病病例 报告给CDC的数据显示,自2009年美国的历史低点以来增加了92%。然而,真正的发病率 据估计,美国每年约有150万例。抗生素耐药性的传播已经严重 治疗选择有限--目前,头孢曲松是唯一获批的一线治疗药物。一种安全有效的 迫切需要淋病疫苗。脂寡糖(LOS)是最丰富的分子上的 淋球菌表面,并在细菌毒力中发挥多方面的作用。mAb 2C 7识别的LOS表位 Ng突变体(因此称为2C 7表位)在体内由>95%的Ng表达;不表达2C 7表位的Ng突变体在体内由>95%的Ng表达。 表位在小鼠中被减弱。我们的小组已经开发了2C 7表位的肽模拟物(模拟表位), 当被配置为多抗原肽(MAP)时,其增强杀菌性Ab并减弱Ng定植, 小鼠此外,我们已经阐明了MAP作为补体介导的杀伤(杀伤)的作用机制。 通过膜攻击复合物),强烈提示血清杀菌活性作为机制相关性 保护。在与Evaxion Biotech的合作项目中,我们筛选了30种抗原, EDEN,Evaxion专有的计算机平台,用于小鼠免疫原性、杀菌活性和功效 阴道定植模型。这些研究确定了两种细胞分裂蛋白作为有希望的候选者, 体内功效当被配置为融合蛋白(嵌合体)时,细胞分裂蛋白表现出改善的活性。 与单个蛋白质相比,它在体内具有更高的免疫活性,目前是我们的主要蛋白质疫苗候选者。DNA和mRNA 疫苗已被证明在抗击新冠肺炎大流行方面非常成功。这些平台引发了高 保护水平,已被证明是安全的,是快速适应和经济的。在这里,我们将利用这两个 提供保护性淋球菌抗原的新疫苗平台。多价疫苗的优势在于 更广泛的菌株覆盖范围,提高疗效,也将提高耐药性发展的障碍。在 目的1,我们将评估含有2C 7 LOS模拟表位(PEP 1)的DNA疫苗构建体,该模拟表位被配置为 八聚体多联体(PEP1_OCT)、细胞分裂蛋白嵌合体或两者的组合。血清将 评估抗体滴度和补体依赖性杀菌活性,以及应答的持久性。 将与目前正在开发的这些疫苗的蛋白质版本进行比较。粘膜 还将测量(阴道)Ab应答。将通过ELISpot测量T细胞应答。根据数据, 在体外,将评估前导DNA疫苗制剂在小鼠阴道定殖模型中的功效。 在目标2中,目标1中描述的构建体将使用mRNA疫苗递送平台表达。如在 目的1、检测血清和阴道液中的抗体滴度、血清杀菌活性、T细胞反应 以及前导mRNA疫苗制剂在淋病小鼠模型中的功效。成功完成 这项提案中的工作将确定一种先导淋球菌DNA和/或mRNA疫苗,用于进一步的临床前研究。 发展

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Lisa Ann Lewis其他文献

Lisa Ann Lewis的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Lisa Ann Lewis', 18)}}的其他基金

Development of nucleic acid-based vaccines against gonorrhea
开发基于核酸的淋病疫苗
  • 批准号:
    10624940
  • 财政年份:
    2022
  • 资助金额:
    $ 25.13万
  • 项目类别:
Outer membrane vesicle vaccine against gonococcal and meningcoccal disease
针对淋球菌和脑膜炎球菌疾病的外膜囊泡疫苗
  • 批准号:
    9981532
  • 财政年份:
    2020
  • 资助金额:
    $ 25.13万
  • 项目类别:
Outer membrane vesicle vaccine against gonococcal and meningcoccal disease
针对淋球菌和脑膜炎球菌疾病的外膜囊泡疫苗
  • 批准号:
    10115599
  • 财政年份:
    2020
  • 资助金额:
    $ 25.13万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 25.13万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 25.13万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 25.13万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 25.13万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 25.13万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 25.13万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 25.13万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 25.13万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 25.13万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 25.13万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了